![](/images/graphics-bg.png)
RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma : Evaluation of Recent Outcomes in a Single Institution
Joint Authors
Andrade Campos, Marcio Miguel
Giraldo, Pilar
Lievano, Paola
Grasa, Jose María
Baringo, Teresa
Montes Limón, Anel E.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-09-25
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with 90Y-Ibritumomab tiuxetan.
Patients and Methods.
Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre.
All patients received 0.3 or 0.4 mCi/kg IV (88%) of 90Y-IT; response evaluation was performed 12 weeks after.
Results.
M/F 44.6%/55.4%, mean age 61.45 years (30–85); ECOG 0-1 96.9%.
According to FLIPI score, distribution were good: 58.5%, intermediate: 29.2%, and poor: 12.3%.
Previous therapies: >2: 40% (26).
ORR was 94.6% (53/56).
CR: 85.7%; CR according to previous disease: relapsed disease: 90% (27/30), refractory disease: 42.85% (3/7), consolidation with CR: 92.85% (13/14), and consolidation with PR: 100% (5/5).
Global PR and NR were 8.9% (5) and 5.3% (3), respectively.
Mean OS 63.86 months with a mean follow-up time of 57 months (2–73).
Mean TTP: 52.65 months (95% CI: 43.83–61.48).
Median OS and TTP were not achieved.
No hospital submissions or deaths were registered.
Conclusions.
This study confirms the safety and high efficacy of 90Y-IT in F-NHL patients, RIT in early stage of disease could improve outcomes.
American Psychological Association (APA)
Andrade Campos, Marcio Miguel& Montes Limón, Anel E.& Grasa, Jose María& Lievano, Paola& Baringo, Teresa& Giraldo, Pilar. 2012. RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma : Evaluation of Recent Outcomes in a Single Institution. Journal of Oncology،Vol. 2012, no. 2012, pp.1-5.
https://search.emarefa.net/detail/BIM-470098
Modern Language Association (MLA)
Andrade Campos, Marcio Miguel…[et al.]. RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma : Evaluation of Recent Outcomes in a Single Institution. Journal of Oncology No. 2012 (2012), pp.1-5.
https://search.emarefa.net/detail/BIM-470098
American Medical Association (AMA)
Andrade Campos, Marcio Miguel& Montes Limón, Anel E.& Grasa, Jose María& Lievano, Paola& Baringo, Teresa& Giraldo, Pilar. RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma : Evaluation of Recent Outcomes in a Single Institution. Journal of Oncology. 2012. Vol. 2012, no. 2012, pp.1-5.
https://search.emarefa.net/detail/BIM-470098
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-470098